Novartis announced that its drug Cosentyx (secukinumab) demonstrated statistically significant and clinically meaningful sustained remission in patients with polymyalgia rheumatica (PMR) compared to placebo, according to Phase III REPLENISH trial data published in the New England Journal of Medicine. The trial showed that Cosentyx not only doubled remission rates but also significantly reduced steroid use, a common treatment with serious side effects. The drug met all primary and secondary endpoints with a consistent safety profile and is under regulatory review in the US, EU, and Japan, with further submissions planned in 2026. This development offers new hope for PMR patients, a group with limited advanced treatment options and high steroid dependency.
Novartis will showcase results from multiple clinical trials of Rhapsido (remibrutinib) at the EAACI Congress 2026, including pivotal Phase III data for chronic inducible urticaria and extension data for chronic spontaneous urticaria. The presentatio...
This monthly series highlights five large-cap, dividend-paying stocks trading at significant discounts compared to their historical norms, selected from over 7,500 U.S.-listed companies. The primary list offers an average yield of 4.2%, with two addi...
Novartis announced that Vanrafia (atrasentan) significantly slowed kidney function decline by approximately 34% compared to placebo over 2.5 years in adults with IgA nephropathy, based on Phase III ALIGN study results published in The Lancet. The dru...
